Express News | Werewolf Therapeutics Announces Promising New Development Candidate, Wtx-921, a First-of-Its-Kind Il-10 Indukine™ Molecule for Inflammatory Diseases

ReutersOct 31 08:04 ET

Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a First-of-its-kind IL-10 INDUKINE Molecule for Inflammatory Diseases

GlobeNewswireOct 31 08:00 ET

Is Werewolf Therapeutics (NASDAQ:HOWL) A Risky Investment?

Simply Wall StOct 23 08:38 ET

12 Health Care Stocks Moving In Tuesday's Intraday Session

BenzingaOct 22 12:30 ET

Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

GlobeNewswireOct 4 09:00 ET

BofA Securities Maintains Werewolf Therapeutics(HOWL.US) With Buy Rating, Maintains Target Price $10

Moomoo NewsSep 10 06:31 ET · Ratings